Duloxetine and Rasagiline interaction

Duloxetine and Rasagiline: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Duloxetine label · effective 2026-03-02

Major

Duloxetine Delayed-Release Capsules are contraindicated in patients who are using or within 14 days of stopping an MAOI intended to treat psychiatric disorders because of an increased risk of serotonin syndrome.

Contraindicationsby drug classView label on DailyMed
Major

Allow at least 5 days after stopping Duloxetine Delayed-Release Capsules prior to initiation of an MAOI to treat psychiatric disorders. [see Dosage and Administration ( 2.7 ), Warnings and Precautions ( 5.4 )]. who are using other MAOIs such as linezolid or intravenous methylene blue because of an increased risk of serotonin syndrome [see Dosage and Administration…

Contraindicationsby drug classView label on DailyMed
Major

Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs ( 4 )

Contraindicationsby drug classView label on DailyMed
Major

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone.

Warnings and precautionsby drug classView label on DailyMed
Major

The concomitant use of Duloxetine Delayed-Release Capsules with MAOIs is contraindicated.

Warnings and precautionsby drug classView label on DailyMed

From the Rasagiline label · effective 2020-06-30

Major

May cause serotonin syndrome when used with antidepressants ( 5.2 )

Warnings and precautionsby drug classView label on DailyMed
Major

In the postmarketing period, potentially life-threatening serotonin syndrome has been reported in patients treated with antidepressants concomitantly with rasagiline.

Warnings and precautionsby drug classView label on DailyMed
Major

Concomitant use of rasagiline with one of many classes of antidepressants (e.g., SSRIs, SNRIs, triazolopyridine, tricyclic or tetracyclic antidepressants) is not recommended [see Drug Interactions ( 7.5 )].

Warnings and precautionsby drug classView label on DailyMed
Moderate

Although a small number of rasagiline-treated patients were concomitantly exposed to antidepressants (tricyclics n=115; SSRIs n=141), the exposure, both in dose and number of subjects, was not adequate to rule out the possibility of an untoward reaction from combining these agents.

Warnings and precautionsby drug classView label on DailyMed
Moderate

Because of the long half-lives of certain antidepressants (e.g., fluoxetine and its active metabolite), at least five weeks (perhaps longer, especially if fluoxetine has been prescribed chronically and/or at higher doses) should elapse between discontinuation of fluoxetine and initiation of rasagiline [see Drug Interactions ( 7.5 )] .

Warnings and precautionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.